Who owns TG THERAPEUTICS, INC. (GTHX)? Elite investor 13F holders

5 tracked elite investors reported holding TG THERAPEUTICS, INC as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC, Bridgewater Associates, Gotham Asset Management, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawTG THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:00186840392.00 USD3400808.000000SharesaddOriginal filing
Renaissance Technologies LLCTG THERAPEUTICS INCSHARE2026-06-302026-08-13 00:00:0037320742.00 USD679300.000000SharesaddOriginal filing
Bridgewater AssociatesTG THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:0023618926.00 USD429904.000000SharesaddOriginal filing
Gotham Asset ManagementTG THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:002467081.00 USD44905.000000SharesreduceOriginal filing
Ancora Advisors / Ancora HoldingsTG THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:0016482.00 USD300.000000SharesreduceOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown